Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Inclusion Criteria: * Histologically or cytologically proven diagnosis of breast cancer (invasive ductal, lobular, medullary, papillary, colloid, tubular) * Completion of standard of care treatment for local and regional disease with no known residual * American Joint Committee on Cancer (AJCC) (6th edition, 2002) Stage IV ( Any T, Any N, M1) based upon the following minimum diagnostic workup: * History/physical examination within 8 weeks prior to registration * Computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET) CT of the whole body within 60 days prior to registration * MRI of the brain, if clinically indicated * Documentation of 1-5 sites of metastatic tumor; each individual site of tumor must be =\< 10 cm or \< 500 cc volume and amenable to radiation therapy as seen on standard imaging (CT, MRI, bone scan) * Pathology from at least one metastatic site confirming breast primary is recommended * Zubrod performance status =\< 2 (Karnofsky \>= 60%) * Absolute neutrophil count (ANC) \>= 1,800 cells/mm\^3 * Platelets \>= 100,000 cells/mm\^3 * Hemoglobin \>= 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 8.0 g/dl is acceptable) * Total bilirubin within institutional limits * Albumin \> 2.9 g/dl * Alkaline phosphatase \< 2.5x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 x ULN * Room air saturation (saturated oxygen \[Sa02\]) \> 90% * Life expectancy \> 3 months * Patient complete study specific informed consent process and sign consent form prior to study entry * Patients with prior metastatic treatment are eligible if they have been disease free for \> 3 years; participants may receive hormonal and Herceptin treatment at any time Exclusion Criteria: * Patients are ineligible if they have had prior treatment for their metastatic disease within 3 years * Prior radiotherapy that would result in overlap of radiation therapy fields * Co-existing or prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) * Severe, active co-morbidity, defined as follows: * Clinically significant pulmonary dysfunction, cardiomyopathy, any history of clinically significant congestive heart failure (CHF), unstable angina pectoris, or cardiac arrhythmia * Transmural myocardial infarction within the last 6 months * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol * Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immunocompromised patients * Pregnancy, breast feeding or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during treatment and for at least three months following completion; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic * Prior treatment with anti-angiogenic therapy * Significant atelectasis such that CT definition of the gross tumor volume (GTV) is difficult to determine * Exudative, bloody or cytologically malignant effusions * Evidence of pleural or pericardial effusion prior to study start; patients with pleural effusion that is transudative, cytologically negative, and non-bloody are eligible; if a pleural effusion is too small for diagnostic thoracentesis, the patient will be eligible